慢性神经系统疾病儿童COVID-19住院结局与多病共存分析
脑瘫、癫痫、遗传性神经异常和神经肌肉疾病与重症COVID-19风险升高相关,且合并症越多风险越高。
要点
- 慢性神经系统疾病患儿占COVID-19住院病例18.7%,其中79.2%合并≥2种慢性病。
- 脑瘫、癫痫、遗传性神经异常及神经肌肉疾病与重症COVID-19风险升高相关。
- 神经系统疾病患儿合并症数量与重症风险呈剂量反应关系,≥4种合并症aPR达2.86。
核心结论
- 慢性神经系统疾病儿童和青少年重症COVID-19风险显著升高,多病共存者风险最高。
- 许多神经系统疾病患儿未接种SARS-CoV-2疫苗,可能受益于促进疫苗接种的措施。
研究设计与样本
- 通过加拿大儿科监测项目和加拿大免疫监测ACTive项目实施,采用混合效应稳健Poisson回归估计调整患病率比(aPR)。
主要发现
- 601例(18.7%)有慢性神经系统疾病,其中476/601(79.2%)合并≥2种慢性病。
- 重症COVID-19与脑瘫(aPR 1.30,95%CI 1.08-1.57)、癫痫(aPR 1.50,95%CI 1.14-1.96)、遗传性神经异常(aPR 1.41,95%CI 1.18-1.67)和神经肌肉疾病(aPR 1.37,95%CI 1.08-1.75)相关。
- 与无合并症病例相比,神经系统疾病病例合并症数量增加与重症COVID-19关联呈剂量反应关系:1种合并症aPR 1.29(95%CI 1.03-1.62),≥4种合并症aPR 2.86(95%CI 2.11-3.87)。
关键数值与推荐
- 重症COVID-19定义为入住重症监护室、通气/血流动力学支持、全身性并发症和/或死亡。
- 多病共存定义为≥2种慢性合并症。
临床怎么用
- 对慢性神经系统疾病患儿,尤其合并多病共存者,应视为重症COVID-19高风险人群加强防护。
- 关注神经系统疾病患儿SARS-CoV-2疫苗接种状态,积极鼓励接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the association between chronic neurologic disorders (NDs) and severe COVID-19 among hospitalized children and youth, and assess how multimorbidity (ie, ≥2 chronic comorbidities) modifies this association. STUDY DESIGN: We conducted a national surveillance study at 13 children's hospitals in Canada from April 2020 to December 2022, via the Canadian Paediatric Surveillance Program and Canadian Immunization Monitoring Program, ACTive. Eligible cases were aged <17 years old and hospitalized for COVID-19. Chronic comorbidities were classified using the Medical Dictionary for Regulatory Activities. Severe COVID-19 was defined as intensive care unit admission, ventilatory/hemodynamic support, systemic complications, and/or death. Mixed-effects robust Poisson regression was conducted to estimate adjusted prevalence ratios (aPRs) between NDs and severe COVID-19, with interaction terms accounting for multimorbidity. RESULTS: Among 3218 cases hospitalized for COVID-19, 601 (18.7%) had NDs. Most cases with NDs had ≥2 chronic comorbidities (n = 476/601, 79.2%). Severe COVID-19 was more common among cases with cerebral palsy (aPR 1.30, 95% CI 1.08-1.57), epilepsy (aPR 1.50, 95% CI 1.14-1.96), genetic disorders with neurologic abnormalities (aPR 1.41, 95% CI 1.18-1.67), and neuromuscular disorders (aPR 1.37, 95% CI 1.08-1.75). Compared with cases without comorbidities, there was a dose-response relationship among ND cases in which additional comorbidities increased associations with severe COVID-19 (eg, aPR 1.29 [95% CI 1.03-1.62] for cases with 1 comorbidity; aPR 2.86 [95% CI 2.11-3.87] for cases with ≥ 4 comorbidities). CONCLUSIONS: Children and youth with NDs are disproportionately affected by severe COVID-19, and patients with multimorbidity were at greatest risk. Many cases with NDs remained unvaccinated against SARS-CoV-2 and may benefit from efforts to encourage vaccine uptake.
引用
- Farrar DS, Huang RS, Donner EJ, et al. Outcomes and Multimorbidity among Children and Youth with Chronic Neurologic Disorders Hospitalized for COVID-19: A Canadian Immunization Monitoring Program, ACTive Study. J Pediatr. 2026. PMID: 41620077. doi:10.1016/j.jpeds.2026.115012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。